Daily2d
FDA approves vimseltinib for tenosynovial giant cell tumor
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...
FiercePharma2d
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Pharmabiz2d
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval: Osaka Friday, February 21, 2025, 15:00 Hrs [IST] Ono Pharmaceutical, one of the la ...
MM&M2d
Rx Rundown: Moderna, Sanofi, GSK and more
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
PharmaTimes3d
FDA approves Deciphera’s Romvimza for rare tumour type
The US Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ Romvimza (vimseltinib) to treat adults with ...
BioWorld4d
Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
Monthly Prescribing Reference5d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
ENDPOINTS NEWS5d
FDA ap­proves Ono’s rare joint tu­mor drug, set­ting up bat­tle with Dai­ichi
FDA approves Ono Pharmaceutical's Romvimza for TGCT, meaning it will compete with Daiichi Sankyo's Turalio. Drug shows better ...